Syngene Supercharges ADC Production with New GMP Facility

Syngene International Limited, a leading contract research, development, and manufacturing organisation (CRDMO), is expanding its capabilities with the establishment of a new GMP bioconjugation suite at its commercial biologics facility (Unit 3) in Bengaluru.

The state-of-the-art, OEB-5-rated facility will offer end-to-end services for antibody–drug conjugates (ADCs) — spanning discovery, process development, and GMP manufacturing. Expected to become operational within this financial year, the new suite will enable monoclonal antibody (mAb) production and bioconjugation at a single site, streamlining ADC development and reducing turnaround times.

Building on over a decade of ADC expertise, including experience with high-potency payloads and linker technologies, Syngene aims to further expand its commercial-scale bioconjugation capabilities while continuing to support clinical-stage programs. The facility will also provide process development, analytical characterisation, and scale-up services for both early- and late-stage ADC programs, reinforcing Syngene’s position as a global partner in advanced biologics development.

News by Rahul Yelligetti.